What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?
- PMID: 38581432
- PMCID: PMC11326810
- DOI: 10.1093/infdis/jiae179
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?
Abstract
Background: With coronavirus disease 2019 (COVID-19) vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward.
Methods: We developed a Markov model representing the potential clinical/economic outcomes from an individual perspective in the United States of getting versus not getting an annual COVID-19 vaccine.
Results: For an 18-49 year old, getting vaccinated at its current price ($60) can save the individual on average $30-$603 if the individual is uninsured and $4-$437 if the individual has private insurance, as long as the starting vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ≥50% and the weekly risk of getting infected is ≥0.2%, corresponding to an individual interacting with 9 other people in a day under Winter 2023-2024 Omicron SARS-CoV-2 variant conditions with an average infection prevalence of 10%. For a 50-64 year old, these cost-savings increase to $111-$1278 and $119-$1706 for someone without and with insurance, respectively. The risk threshold increases to ≥0.4% (interacting with 19 people/day), when the individual has 13.4% preexisting protection against infection (eg, vaccinated 9 months earlier).
Conclusions: There is both clinical and economic incentive for the individual to continue to get vaccinated against COVID-19 each year.
Keywords: COVID-19; booster; economic; individual; model; vaccination.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest . P. J. H., M. E. B., and U. S. are coinventors of a COVID-19 recombinant protein vaccine technology owned by Baylor College of Medicine (BCM) that was recently licensed by BCM nonexclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. The coinventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries that result in a commercial license, a share of any royalty income, according to BCM policy. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.Lancet Infect Dis. 2021 Jul;21(7):962-974. doi: 10.1016/S1473-3099(21)00079-7. Epub 2021 Mar 18. Lancet Infect Dis. 2021. PMID: 33743846 Free PMC article.
-
Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.Expert Rev Vaccines. 2024 Jan-Dec;23(1):730-739. doi: 10.1080/14760584.2024.2383343. Epub 2024 Aug 5. Expert Rev Vaccines. 2024. PMID: 39072472
-
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023. Front Immunol. 2023. PMID: 37915583 Free PMC article.
-
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):177-181. doi: 10.15585/mmwr.mm7105e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35113851 Free PMC article.
-
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081. Epidemiol Prev. 2023. PMID: 38314543 Review. English.
References
-
- American Hospital Association . CMS eliminates COVID-19 vaccination requirements for health care workers. https://www.aha.org/news/headline/2023-05-31-cms-eliminates-covid-19-vac.... Accessed 10 January 2024.
-
- Shear MD, Weiland N. White house will end most covid vaccine mandates. https://www.nytimes.com/2023/05/01/us/politics/us-covid-vaccine-mandates.... Accessed 10 January 2024.
-
- The White House . The Biden-Harris administration will end COVID-19 vaccination requirements for federal employees, contractors, international travelers, head start educators, and CMS-certified facilities. Washington, DC: The White House, 2023.
-
- Centers for Disease Control and Prevention . CDC COVID-19 vaccination program provider requirements and support. https://www.cdc.gov/vaccines/covid-19/vaccination-provider-support.html. Accessed 10 January 2024.
-
- Kates J, Tolbert J. COVID-19 vaccine access for uninsured adults this fall. https://www.kff.org/policy-watch/covid-19-vaccine-access-for-uninsured-a.... Accessed 10 January 2024.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
